QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.004283v1 33/10/1503    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gschwind, H.-P. Articles by Gross, G. Search for Related Content PubMed PubMed Citation Articles by Gschwind, H.-P. Articles by Gross, G.

METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

Novartis Pharma AG, Exploratory Development/Drug Metabolism & Pharmacokinetics, Basel, Switzerland (H.-P.G., U.P., F.W., M.Z., C.S., P.Z., G.G.); Novartis Pharmaceuticals Corporation, Exploratory Development/Bioanalytics & Pharmacokinetics (M.H.), Clinical Pharmacology Oncology (M.B.-A., B.P.), East Hanover, New Jersey; and Swiss Pharma Contract, Clinical Pharmacology & Clinical Research, Allschwil, Switzerland (R.P., M.S.)

Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male healthy volunteers after a single oral dose of 239 mg of ¹⁴C-labeled imatinib mesylate. Biological fluids were analyzed for total radioactivity, imatinib, and its main metabolite CGP74588. Metabolite patterns were determined by radio-high-performance liquid chromatography with off-line microplate solid scintillation counting and characterized by liquid chromatography-mass spectrometry. Imatinib treatment was well tolerated without serious adverse events. Absorption was rapid (t_max 1-2 h) and complete with imatinib as the major radioactive compound in plasma. Maximum plasma concentrations were 0.921 ± 0.095 µg/ml (mean ± S.D., n = 4) for imatinib and 0.115 ± 0.026 µg/ml for the pharmacologically active N-desmethyl metabolite (CGP74588). Mean plasma terminal elimination half-lives were 13.5 ± 0.9 h for imatinib, 20.6 ± 1.7 h for CGP74588, and 57.3 ± 12.5 h for ¹⁴C radioactivity. Imatinib was predominantly cleared through oxidative metabolism. Approximately 65 and 9% of total systemic exposure [AUC_{0-24 h} (area under the concentration time curve) of radioactivity] corresponded to imatinib and CGP74588, respectively. The remaining proportion corresponded mainly to oxidized derivatives of imatinib and CGP74588. Imatinib and its metabolites were excreted predominantly via the biliary-fecal route. Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine). Approximately 28 and 13% of the dose in the excreta corresponded to imatinib and CGP74588, respectively.

This article has been cited by other articles:

				S. Hu, R. M. Franke, K. K. Filipski, C. Hu, S. J. Orwick, E. A. de Bruijn, H. Burger, S. D. Baker, and A. Sparreboom Interaction of Imatinib with Human Organic Ion Carriers Clin. Cancer Res., May 15, 2008; 14(10): 3141 - 3148. [Abstract] [Full Text] [PDF]

				R. K. Ramanathan, M. J. Egorin, C. H.M. Takimoto, S. C. Remick, J. H. Doroshow, P. A. LoRusso, D. L. Mulkerin, J. L. Grem, A. Hamilton, A. J. Murgo, et al. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group J. Clin. Oncol., February 1, 2008; 26(4): 563 - 569. [Abstract] [Full Text] [PDF]

				J. Gibbons, M. J. Egorin, R. K. Ramanathan, P. Fu, D. L. Mulkerin, S. Shibata, C. H.M. Takimoto, S. Mani, P. A. LoRusso, J. L. Grem, et al. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group J. Clin. Oncol., February 1, 2008; 26(4): 570 - 576. [Abstract] [Full Text] [PDF]

				N. P. van Erp, H. Gelderblom, M. O. Karlsson, J. Li, M. Zhao, J. Ouwerkerk, J. W. Nortier, H.-J. Guchelaar, S. D. Baker, and A. Sparreboom Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib Clin. Cancer Res., December 15, 2007; 13(24): 7394 - 7400. [Abstract] [Full Text] [PDF]

				A. V. Boddy, J. Sludden, M. J. Griffin, C. Garner, J. Kendrick, P. Mistry, C. Dutreix, D. R. Newell, and S. G. O'Brien Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia Clin. Cancer Res., July 15, 2007; 13(14): 4164 - 4169. [Abstract] [Full Text] [PDF]

				J. Li, M. O. Karlsson, J. Brahmer, A. Spitz, M. Zhao, M. Hidalgo, and S. D. Baker CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors J Natl Cancer Inst, December 6, 2006; 98(23): 1714 - 1723. [Abstract] [Full Text] [PDF]

				L. M. Jost, H.-P. Gschwind, T. Jalava, Y. Wang, C. Guenther, C. Souppart, A. Rottmann, K. Denner, F. Waldmeier, G. Gross, et al. Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients Drug Metab. Dispos., November 1, 2006; 34(11): 1817 - 1828. [Abstract] [Full Text] [PDF]